<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment with digoxin: Initial dosing, monitoring, and dose modification</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment with digoxin: Initial dosing, monitoring, and dose modification</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment with digoxin: Initial dosing, monitoring, and dose modification</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian Olshansky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiac glycosides have important positive inotropic, neurohormonal, and electrophysiologic actions, which are the basis for its use in two clinical situations: heart failure due to systolic dysfunction, and in certain supraventricular tachyarrhythmias. The ability of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> to reduce sympathetic activation has also been recognized. For maximal early benefits in treating tachyarrhythmias, digoxin requires loading doses, which can be administered intravenously or orally. </p><p>Studies show that <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> use is declining but is still prevalent. Using Medicare Part D data from 2013 to 2019, total digoxin prescriptions (4.6 to 1.8 million) and proportion of digoxin prescribers decreased (9.1 to 4.3 percent overall, 26.6 to 11.8 percent among general medicine prescribers, and 65.4 to 48.9 percent among cardiology) [<a href="#rid1">1</a>]. </p><p>While two cardiac glycosides (<a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> and digitoxin) were previously used, digitoxin has not been widely available since the 1980s. As digoxin is now the only cardiac glycoside available in most countries, the method of initiating therapy with digoxin for patients with atrial fibrillation is presented here. Recommendations regarding the use of digoxin in the management of heart failure or arrhythmias are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a> and  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INITIATION OF THERAPY</span><span class="headingEndMark"> — </span>The electrolyte and renal status of each patient should be ascertained prior to initiating treatment and periodically thereafter. Hypokalemia or hypomagnesemia, for example, may promote the development of digoxin-induced arrhythmias, while impaired renal function may result in higher than anticipated serum drug levels. (See <a class="local">'Dose adjustments'</a> below.)</p><p>The initiation of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> therapy has been divided into rapid and slow digitalization followed by the maintenance digoxin dose, and the proposed regimens vary considerably. The following principles should be viewed as a general guide to the use of digoxin for its inotropic or electrophysiologic effects, which must be modified according to clinical circumstances. Patients receiving digoxin for ventricular rate control in atrial fibrillation or flutter will usually require more rapid loading than those treated with digoxin for heart failure, in whom a loading dose is typically not required. The use of digoxin primarily for heart failure is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p class="headingAnchor" id="H3094965134"><span class="h2">Slow digoxin loading</span><span class="headingEndMark"> — </span>Slow oral digitalization, generally preferred for most patients, can be achieved by starting a maintenance dose of 0.125 to 0.25 mg daily. A steady state will be achieved after five cycles of the drug half-life (T1/2ß), which is approximately 7 to 10 days in the average subject.</p><p class="headingAnchor" id="H2474850"><span class="h2">Rapid digoxin loading</span><span class="headingEndMark"> — </span>Rapid intravenous and oral digitalization can be used to control the ventricular response in atrial fibrillation and flutter. However, other drugs may be more effective and/or have a more rapid onset of action on the ventricular response in these arrhythmias; therefore, rapid digitalization is rarely needed unless alternative drugs are contraindicated or have not been effective. (See  <a class="medical medical_review" href="/z/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1067.html" rel="external">"Control of ventricular rate in atrial flutter", section on 'Rate control with drugs'</a>.)</p><p>The total loading dose with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> varies from patient to patient but is usually between 0.75 to 1.5 mg with intravenous administration and 1 to 1.5 mg with oral administration. (See <a class="local">'Dose adjustment in kidney disease'</a> below and <a class="local">'Patients with low body weight'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous loading</strong> – For ventricular rate control in atrial fibrillation and flutter, the most rapid means of digitalization is the intravenous route. An initial intravenous dose of 0.25 to 0.5 mg of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> is given over several minutes, followed by 0.25 mg every 6 hours for a total loading dose of 0.75 to 1.5 mg (10 to 12 mcg/kg lean body weight) (<a class="calc calc_professional" href="/z/d/html/13407.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/13408.html" rel="external">calculator 2</a>). Intravenous digoxin begins to act in 15 to 30 minutes with a peak effect in 1 to 5 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral loading</strong> – Rapid oral digitalization can be accomplished by giving 0.5 mg initially followed by 0.25 mg every six hours for a total loading dose of 0.75 to 1.5 mg.</p><p></p><p class="headingAnchor" id="H23181621"><span class="h2">Loading dose adjustments</span><span class="headingEndMark"> — </span>Patients who are hypokalemic, hypomagnesemic, hypercalcemic, hypoxic, or with hypothyroidism are more sensitive to the effects of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>. If these issues persist at the time of digoxin loading, an initial loading dose in the lower range (eg, 0.75 mg or less) should be considered.</p><p><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> distributes widely to skeletal muscle, cardiac, and other lean tissue and has a large volume of distribution (ie, 4 to 7 L/kg) in normal subjects, which is decreased in patients who are older, have low skeletal muscle mass, or severe renal impairment. Digoxin serum concentrations relative to the administered loading dose may be proportionally increased among persons with low muscle mass and/or renal impairment, and a reduced loading dose should be considered.</p><p class="headingAnchor" id="H23181628"><span class="h3">Renal impairment</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> loading dose should be reduced by approximately one-third to one-half (or more) in the setting of severe chronic renal insufficiency [<a href="#rid2">2-4</a>]. For most patients with chronic renal insufficiency not on dialysis, the reduced loading dose may be supplemented after six hours if clinical response is inadequate, in absence of toxicity. For patients with stage 5 chronic kidney disease (glomerular filtration rate [GFR] &lt;15 mL/minute), or for those on hemodialysis, chronic ambulatory peritoneal dialysis, or continuous renal replacement therapy, alternative agents (eg, beta blockers or nondihydropyridine calcium channel blockers) may be preferred for heart rate control; however, if digoxin will be used, a reduced loading dose of 3 to 5 mcg/kg (0.25 to 0.375 mg) is recommended, followed by a maintenance dose of 0.0625 mg every 48 hours. (See <a class="local">'Dose adjustment in kidney disease'</a> below.)</p><p class="headingAnchor" id="H23181665"><span class="h3">Lean body weight</span><span class="headingEndMark"> — </span>In general, it is reasonable to select an initial loading dose in the lower range (ie, 0.75 to 1 mg) for patients of low to average lean body weight (eg, 45 to 70 kg) and in the upper part of the dose range (ie, 1 to 1.5 mg) for patients of average to above average lean body weight (eg, 71 to 90 kg) (<a class="calc calc_professional" href="/z/d/html/13407.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/13408.html" rel="external">calculator 2</a>).</p><p class="headingAnchor" id="H23181783"><span class="h3">Patients with low body weight</span><span class="headingEndMark"> — </span>Patients with body weight of less than 45 kg should receive 50 percent of the normal loading dose.</p><p class="headingAnchor" id="H4683113"><span class="h3">Patients who are obese</span><span class="headingEndMark"> — </span>Compared with normal weight subjects, neither volume of distribution nor clearance of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> are consistently altered by changes in body composition associated with obesity [<a href="#rid5">5-7</a>]. Therefore, normal (non-weight based) loading doses should be used. However, if a weight based dose is used, it should be based upon estimated lean body weight (<a class="calc calc_professional" href="/z/d/html/13407.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/13408.html" rel="external">calculator 2</a>).</p><p class="headingAnchor" id="H12454599"><span class="h2">Maintenance digoxin dosing</span><span class="headingEndMark"> — </span>For most patients, the maintenance dose of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> will be between 0.125 mg and 0.25 mg daily. The daily maintenance dose will vary depending on the indication for digoxin therapy, with patients receiving digoxin for heart failure often requiring lower doses than those who are taking digoxin for ventricular rate control. Additionally, the maintenance dose is affected by renal function, body weight, and the presence or absence of other medications which are known to alter the metabolism of digoxin [<a href="#rid8">8</a>]. (See <a class="local">'Dose adjustments'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular rate control – For patients taking <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> for ventricular rate control in the setting of atrial arrhythmias, the typical maintenance dose is between 0.125 and 0.25 mg daily. In contrast to digoxin use for heart failure, there is no particular serum digoxin level which is targeted, as the medication should be adjusted to maintain optimal ventricular rate control. However, serum digoxin levels higher than 1 ng/mL (1.3 nmol/L) should be avoided to reduce the risk of digoxin toxicity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure – The approach to maintenance <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> dosing in patients with heart failure is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p></p><p class="headingAnchor" id="H4682340"><span class="h2">Dose adjustments</span><span class="headingEndMark"> — </span>Bioavailability is between 70 and 80 percent for conventional <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> tablets and between 75 and 85 percent for digoxin elixir, and the T1/2ß of digoxin ranges from 33 to 50 hours when renal function is normal. Unlike certain other drugs (eg, <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>), the bioavailability of the oral dose forms of digoxin does not appear to be affected by heart failure. Dose adjustments of digoxin are necessary in patients with renal dysfunction, patients with low body weight, and with the concomitant use of certain medications. The effect of digoxin in patients with heart failure and the need for dose adjustments in such patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p class="headingAnchor" id="H4682401"><span class="h3">Dose adjustment in kidney disease</span><span class="headingEndMark"> — </span>Approximately 70 to 80 percent of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> is eliminated unchanged in the urine, leading to prolongation of the half-life in patients with renal insufficiency. Renal insufficiency also decreases the extravascular volume of distribution of digoxin, another effect that can elevate plasma drug levels. As a result, <strong>both the initial loading dose and the maintenance dose must be reduced in patients with underlying kidney disease. In end-stage kidney disease, for example, the loading dose should be one-half to two-thirds normal. </strong></p><p class="bulletIndent1"><span class="glyph">●</span>The adjustment of the <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> loading dose is discussed above. (See <a class="local">'Renal impairment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial maintenance dose (for congestive heart failure) adjusted for ideal body weight and renal function (except stage 5 chronic kidney disease or receiving renal replacement therapy) is presented in the table  (<a class="graphic graphic_table graphicRef90157" href="/z/d/graphic/90157.html" rel="external">table 1</a>). (See <a class="local">'Patients requiring hemodialysis'</a> below and  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p></p><p class="headingAnchor" id="H1782461946"><span class="h4">Patients requiring hemodialysis</span><span class="headingEndMark"> — </span>For patients on intermittent hemodialysis (IHD), chronic ambulatory peritoneal dialysis (CAPD), and continuous renal replacement therapy (CRRT), the dosing recommendation is 0.0625 mg every 48 hours, or approximately 10 to 25 percent of the usual dose for patients with normal renal function given every 48 hours [<a href="#rid9">9,10</a>]. No supplemental dose for dialysis is required because renal replacement therapies (eg, IHD, CAPD, CRRT) remove only insignificant amounts of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> from the body due to digoxin's large volume of distribution. Serum digoxin concentrations should be monitored. The same dose recommendation is used for stage 5 chronic kidney disease patients (GFR &lt;15 mL/minute) who are not currently receiving dialysis. (See <a class="local">'Monitoring serum digoxin'</a> below.)</p><p class="headingAnchor" id="H4682492"><span class="h3">Dose adjustment with hepatic disease</span><span class="headingEndMark"> — </span>Hepatic disease has little influence on <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> metabolism or clearance; therefore, no dose adjustment is necessary.</p><p class="headingAnchor" id="H4682539"><span class="h3">Dose adjustment with concomitant medications</span><span class="headingEndMark"> — </span>There are a number of important drug interactions with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>. Some examples are provided below; in addition, specific interactions of digoxin with medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate. </p><p class="bulletIndent1"><span class="glyph">●</span>Inhibitors of P-glycoprotein efflux transporters (eg, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, and <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>) can increase serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> levels. With concurrent dronedarone administration, for example, the digoxin dose should be reduced by one-half if digoxin cannot be discontinued [<a href="#rid11">11-13</a>] (see  <a class="medical medical_review" href="/z/d/html/16216.html" rel="external">"Clinical uses of dronedarone", section on 'Metabolism and drug interactions'</a>). A list of medicines that inhibit P-glycoprotein is provided separately  (<a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inducers of P-glycoprotein (eg, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, etc), on the other hand, can decrease serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> levels. A list of medicines that induce P-glycoprotein is provided separately  (<a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">Cholestyramine</a> and antacids can decrease the intestinal absorption of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> by 20 to 35 percent, necessitating an increase in the daily dose. To avoid these interactions, digoxin should be dosed one hour before or two to three hours after the administration of the antacids or cholestyramine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a>, an antidepressant that is also frequently prescribed to aid in smoking cessation, can decrease <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> levels by 60 percent; monitor serum digoxin levels and clinical status [<a href="#rid14">14-16</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diuretics may increase digitalis toxicity as a result of a decrease in the glomerular filtration rate and the development of electrolyte abnormalities, especially hypokalemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> can interfere with the sequential hydrolysis pathway of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> metabolism (which begins in the stomach and is responsible for less than 15 percent of the metabolism in most patients but which can be significantly more active in a minority of patients). As such, these drugs increase digoxin levels in approximately 10 percent of patients in whom this pathway is a significant component of the drug's metabolism. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High doses of <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">biotin</a> (vitamin B7) can increase the measured serum concentration of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> by as much as 0.25 ng/mL (0.3 nmol/L) when measured using the luminescent oxygen channeling immunoassay (LOCI) [<a href="#rid17">17</a>]. This does not represent a true increase in serum digoxin concentration but an interaction between biotin and the measurement assay, resulting in the artificial appearance of increased serum digoxin levels. </p><p></p><p class="headingAnchor" id="H4682601"><span class="h3">Digoxin in pregnancy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> crosses the placenta and has been used for both fetal and maternal cardiac indications without report of fetal harm or teratogenicity [<a href="#rid18">18</a>]. As such, there is no contraindication for using digoxin during pregnancy or during lactation.</p><p class="headingAnchor" id="H4682607"><span class="h3">Digoxin in patients with amyloidosis</span><span class="headingEndMark"> — </span>The use and safety of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> in patients with amyloidosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/85952.html" rel="external">"Cardiac amyloidosis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/85952.html" rel="external">"Cardiac amyloidosis: Treatment and prognosis", section on 'Therapies to avoid or use with caution'</a>.) </p><p class="headingAnchor" id="H3"><span class="h1">MONITORING SERUM DIGOXIN</span></p><p class="headingAnchor" id="H12105027"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Given the relatively narrow therapeutic window of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, with substantial overlap between so-called therapeutic and toxic levels, patients taking digoxin require monitoring of the serum digoxin concentration, with the "optimal" level varying with the clinical setting. Monitoring the serum digoxin level is particularly important in persons with chronic renal dysfunction or rapidly changing renal function, as significantly decreased renal function can lead to accumulation of digoxin and its metabolites and predispose to digoxin toxicity. Additionally, patients with electrolyte disturbances, particularly hypokalemia and hypomagnesemia, which may be related to diuretic therapy or other medications, are at increased risk for digoxin-associated arrhythmias and should undergo monitoring of the serum digoxin level until serum potassium level and magnesium concentration return to the normal range [<a href="#rid19">19</a>]. (See <a class="local">'Dose adjustments'</a> above and  <a class="medical medical_review" href="/z/d/html/944.html" rel="external">"Cardiac arrhythmias due to digoxin toxicity", section on 'Plasma digoxin levels associated with toxicity'</a>.)</p><p>Monitoring the serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration is most important when digoxin is used in the treatment of heart failure with systolic dysfunction, whereas levels are only checked when used in patients with atrial fibrillation if toxicity is suspected. Blood samples should be obtained at least 6 hours, but optimally 12 hours, after administration of digoxin to ensure completion of distribution from the blood to the tissues. In patients with advanced kidney disease or who are on hemodialysis, the digoxin level should be checked at least 12 to 24 hours after the prior dose. Serum digoxin concentrations measured prior to these times may be falsely elevated. </p><p class="headingAnchor" id="H2161374"><span class="h2">Adjusting the digoxin dose</span><span class="headingEndMark"> — </span>Assuming that the <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> level was drawn at the correct time, at steady state, and under conditions of stable renal function, there is a linear relationship between digoxin dose and serum concentration. As an example, a steady state concentration is measured and returns at 1.6 ng/mL (2.05 nmol/L) in a patient taking a daily maintenance dose (for this example, 0.25 mg daily). Assuming the desired serum concentration is 0.8 ng/mL (1.0 nmol/L), the dose should be reduced by 50 percent (to 0.125 mg daily in this example). The same linear relationship is true for patients whose serum concentration is lower than desired in whom a dose increase is needed.</p><p class="headingAnchor" id="H4"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>The monitoring of serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> levels in patients with heart failure is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Atrial fibrillation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> is generally less effective for rate control of atrial fibrillation (AF) than beta blockers or calcium channel blockers, is less likely to control the ventricular rate during exercise (when vagal tone is low and sympathetic tone is high), has little or no ability to terminate the arrhythmia, and often does not slow the heart rate with recurrent AF. Thus, patients frequently require the addition of a beta blocker or calcium channel blocker for optimal rate control. (See  <a class="medical medical_review" href="/z/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a>.)</p><p>When <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> is used strictly for ventricular rate control in AF, serum digoxin levels should be monitored periodically, although the drug concentration often does not correlate with ventricular rate control and is used more as a guide to toxicity than to therapy. Junctional escape beats (as detected by the equality of all the longest observed R-R intervals on the electrocardiogram) are common when digitalis has successfully slowed the ventricular rate. Giving more digoxin in this setting will increase the degree of AV nodal block and produce periods of regular junctional rhythm. The change from single junctional escapes to periodic junctional rhythm usually signifies the development of digoxin toxicity. (See  <a class="medical medical_review" href="/z/d/html/944.html" rel="external">"Cardiac arrhythmias due to digoxin toxicity", section on 'Junctional rhythm, tachycardia, and bradycardia'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Relation to digoxin toxicity</span><span class="headingEndMark"> — </span>Digoxin-related cardiac arrhythmias and extracardiac symptoms can occur when the serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> concentration is in the therapeutic or even subtherapeutic range; as a result, the presence of digoxin toxicity or excess is often a <strong>clinical diagnosis</strong> irrespective of circulating levels (unless of course the value is zero). (See  <a class="medical medical_review" href="/z/d/html/944.html" rel="external">"Cardiac arrhythmias due to digoxin toxicity"</a>.)</p><p class="headingAnchor" id="H2474884"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– Cardiac glycosides such as <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> have positive inotropic, neurohormonal, and electrophysiologic actions which are the basis for its use in two clinical situations: heart failure with reduced ejection fraction, and in certain supraventricular tachyarrhythmias, primarily atrial fibrillation (AF) and atrial flutter. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Slow </strong><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a><strong> loading </strong>– This approach is preferred for most patients. A slow digoxin load is achieved by starting a maintenance oral dose of 0.125 to 0.25 mg daily, which results in a steady state serum level of drug in approximately 7 to 10 days in the average subject. (See <a class="local">'Slow digoxin loading'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid </strong><a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a><strong> loading </strong>– This approach can be used to control the ventricular response in AF and atrial flutter (see <a class="local">'Rapid digoxin loading'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial intravenous doses of 0.25 to 0.5 mg of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> are given over several minutes, followed by 0.25 mg every six hours for a total dose of 0.75 to 1.5 mg with appropriate dosing adjustments for kidney disease and the concomitant use of certain medications. (See <a class="local">'Dose adjustment in kidney disease'</a> above and <a class="local">'Dose adjustment with concomitant medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rapid oral <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> loading can be accomplished by giving 0.5 mg initially followed by 0.25 mg every six hours for a total loading dose of 0.75 to 1.5 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring considerations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Narrow therapeutic window </strong>– Given the relatively narrow therapeutic window of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> and substantial overlap between therapeutic and toxic levels, patients taking digoxin require monitoring of the serum digoxin concentration. The optimal level of digoxin varies according to clinical setting. Monitoring the serum digoxin level is particularly important in persons with chronic kidney disease, rapidly changing kidney function, or electrolyte disturbances (eg, hypokalemia, hypomagnesemia). (See <a class="local">'Monitoring serum digoxin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose adjustments </strong>– Assuming that the <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> level was drawn at the correct time, at steady state, and under conditions of stable kidney function, there is a linear relationship between digoxin dose and serum concentration that should be followed for any necessary dose adjustments. (See <a class="local">'Adjusting the digoxin dose'</a> above.)</p><p></p><p class="bulletIndent2">When <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> is used strictly for ventricular rate control in AF, serum digoxin levels should be monitored periodically, although the drug concentration often does not correlate with ventricular rate control and is used more as a guide to toxicity than to therapy. (See <a class="local">'Atrial fibrillation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with kidney disease </strong>– Approximately 70 to 80 percent of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> is eliminated in the urine; thus, the half-life of digoxin is prolonged in patients with kidney disease. Kidney disease also decreases the extravascular volume of distribution of digoxin, another effect that can elevate plasma drug levels. As a result, we reduce both the initial loading dose and the maintenance dose in patients with kidney disease  (<a class="graphic graphic_table graphicRef90157" href="/z/d/graphic/90157.html" rel="external">table 1</a>). (See <a class="local">'Dose adjustment in kidney disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with concomitant medications </strong>– <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">Quinidine</a>, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> (medications that inhibit P-glycoprotein efflux transporters) can increase serum <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> levels, thereby requiring a reduction in the daily digoxin dose  (<a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 2</a>). Inducers of P-glycoprotein (eg, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, etc), on the other hand, can decrease serum digoxin levels. </p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">Cholestyramine</a> and antacids can decrease the intestinal absorption of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>. This necessitates spacing of the doses or an increase in the daily digoxin dose. </p><p></p><p class="bulletIndent2">Specific interactions of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate. (See <a class="local">'Dose adjustment with concomitant medications'</a> above.)</p><p></p><p class="headingAnchor" id="H3739109356"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lynne Sylvia, PharmD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">See C, Wheelock KM, Caraballo C, et al. Patterns of Digoxin Prescribing for Medicare Beneficiaries in the United States 2013-2019. Am J Med 2023.</a></li><li><a class="nounderline abstract_t">Aronson JK. Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. Clin Pharmacokinet 1983; 8:155.</a></li><li><a class="nounderline abstract_t">Cheng JW, Charland SL, Shaw LM, et al. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Pharmacotherapy 1997; 17:584.</a></li><li><a class="nounderline abstract_t">Matzke GR, Frye RF. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf 1997; 16:205.</a></li><li><a class="nounderline abstract_t">Ewy GA, Groves BM, Ball MF, et al. Digoxin metabolism in obesity. Circulation 1971; 44:810.</a></li><li><a class="nounderline abstract_t">Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update. Clin Pharmacokinet 1986; 11:199.</a></li><li><a class="nounderline abstract_t">Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30:18.</a></li><li><a class="nounderline abstract_t">DiDomenico RJ, Bress AP, Na-Thalang K, et al. Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. Pharmacotherapy 2014; 34:1121.</a></li><li class="breakAll">Caroline Ashley and Aileen Dunleavy. Digoxin. In: The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioners, 5th edition, CRC Press, Boca Raton 2018. p.330.</li><li><a class="nounderline abstract_t">Mooradian AD. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet 1988; 15:165.</a></li><li><a class="nounderline abstract_t">Vallakati A, Chandra PA, Pednekar M, et al. Dronedarone-induced digoxin toxicity: new drug, new interactions. Am J Ther 2013; 20:e717.</a></li><li><a class="nounderline abstract_t">Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 2010; 15:15S.</a></li><li class="breakAll">Dronedarone tablet. US Food &amp; Drug Administration (FDA) approved product information. Revised March, 2014. US National Library of Medicine. Available online at http://www.dailymed.nlm.nih.gov/.</li><li><a class="nounderline abstract_t">Kirby BJ, Collier AC, Kharasch ED, et al. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos 2012; 40:610.</a></li><li><a class="nounderline abstract_t">He J, Yu Y, Prasad B, et al. Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction. Biopharm Drug Dispos 2014; 35:253.</a></li><li class="breakAll">Bupropion US prescribing information (revision May 10, 2017) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020711s045s046s047lbl.pdf.</li><li><a class="nounderline abstract_t">Rodriguez JJ, Acosta F, Bourgeois L, Dasgupta A. Biotin at High Concentration Interferes with the LOCI Digoxin Assay but the PETINIA Phenytoin Assay Is Not Affected. Ann Clin Lab Sci 2018; 48:164.</a></li><li><a class="nounderline abstract_t">Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99:1265.</a></li><li><a class="nounderline abstract_t">Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009; 151:755.</a></li></ol></div><div id="topicVersionRevision">Topic 1051 Version 55.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Patterns of Digoxin Prescribing for Medicare Beneficiaries in the United States 2013-2019</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6342898" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9165563" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9098657" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5115072" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Digoxin metabolism in obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3524955" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Drug disposition in obese humans. An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625670" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dosing of medications in morbidly obese patients in the intensive care unit setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25164709" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25164709" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3052985" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21519214" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dronedarone-induced digoxin toxicity: new drug, new interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472816" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472816" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22190694" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24436229" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24436229" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29678842" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Biotin at High Concentration Interferes with the LOCI Digoxin Assay but the PETINIA Phenytoin Assay Is Not Affected.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10069797" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Digitalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19920278" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hypomagnesemia induced by several proton-pump inhibitors.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
